- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04285775
A Novel Device for Surveillance of Vascular Access Sites for Bleeding
Background Bleeding is often encountered after vascular access procedures for dialysis and fatal episodes of haemorrhage has been reported. A technological solution was sought to monitor for such rare but potentially catastrophic incidents. A novel device, BWATCH, was developed to detect fresh blood from wounds.
Aims The aim of this clinical trial was to evaluate the sensitivity and specificity of the device in detecting bleeding in a clinical environment.
Methods This a prospective, observational study on inpatients who will have a dialysis catheter inserted or removed. The device will be placed over the dressing for at least 6 hours. An alarm will be triggered if the device detects moisture and wavelength of light reflected specific for haemoglobin.
Study Overview
Status
Conditions
Detailed Description
Background
Post-procedural wound hemorrhage is a potential complication following any invasive procedure. In the setting of hemodialysis, with multiple repeated vascular access procedures performed on uremic patients prone to bleeding, post-procedural bleeding would not be infrequent.
Serious adverse events following central venous catheter removal, while rare, were not isolated incidents. The British National Reporting and Learning System, reported 6 incidents of late bleeding following femoral line removal over 3 years. Of these, 3 resulted in deaths and 2 suffered more than one litre of blood loss. The UK Renal Association, British Renal Society and Intensive Care Society subsequently released a recommendation for the safe removal of a temporary femoral dialysis line in 2019. Protocols implemented in some units required an intense period of monitoring every 5-15 minutes in the first 2 hours.
However, frequent monitoring protocols places additional demands on already scarce nursing manpower. As catastrophic bleeding is rare, it is difficult to expect healthcare staff to maintain a consistent high level of vigilance for such a low probability event. The possibility of missed catastrophic bleeding is always present, particularly if the patient is incapacitated and unable to call for assistance.
A technological solution to safely monitor patients for bleeding following catheter removal is needed. Ideally, this technology should also be applicable for other wounds at risk of severe bleeding, for example, after arterial access for coronary angiogram or vascular interventions. There were no commercially available devices which fully met the user requirements, which included ease of use, wireless, compact form factor and specific detection of bleeding with no direct contact with the wound or blood. A compact device was developed
Through a research collaboration between a hospital and a technology and design university, supported by a national innovation grant, a device was developed to monitor wound for bleeding. By the end of 2018, a working prototype - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH) - was available for first-in-human clinical trials. The technological concept has been presented in electrical engineering conferences. This is a stand-alone disc-shaped device (approximately 5 cm in diameter and <1 cm thick) which can be placed over dressings and continuous monitoring for bleeding will take place. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient.
Objectives
The primary aim of this clinical trial was to evaluate the sensitivity of the device in detecting bleeding in a clinical environment. The secondary aim is to determine the specificity of the device for actual bleeding (false positive rates).
Materials and Methods
This study has been reviewed and approved by the institutional review board (Singhealth cIRB 2014-2036).
This a prospective, observational study performed in an acute care hospital. Inpatients planned for dialysis catheter insertion or removal based on standard clinical care and indications will be identified fro recruitment.
Consent will be obtained from the patient or their legal representative if cognitively impaired. As part of standard care, the procedurist will secure haemostasis following the procedure and apply a bandage. The investigators will then place the device over the dressing and secure it in place. The device will then be left in-situ for at least 6 hours. Any alarms triggered and bleeding episodes will be documented in a case report form.
For safety, throughout the observation period, routine monitoring and inspection for bleeding by the nurse-in-charge would continue as per hospital clinical protocol.
Baseline demographic data of the patients will be collected. Laboratory test results collected will include the platelet count, international normalized ratio (INR) and partial thromboplastin time (PTT). The use of any anti-coagulation or anti-platelet medication will be recorded.
From the bleeding incidences and device alarm activation rates, the sensitivity and specificity of the device for detection of true bleeding will be calculated.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 529889
- Changi General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Hospital inpatients planned for dialysis catheter insertion or removal, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
Exclusion Criteria:
- Patients who declined participation, or
- Patients with no legal representatives who were unable to provide consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Insertion of Dialysis Catheter
Hospital inpatients planned for dialysis catheter insertion, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
|
A stand-alone disc-shaped device (approximately 5 cm in diameter and <1 cm thick) which can be placed over dressings.
Once switched on and put in place, continuous monitoring for bleeding takes place.
Detection occurs in 2 phases.
First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance.
Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin.
The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient.
The device can be used over transparent plastic dressings and does not require direct contact with blood.
|
Removal of Dialysis Catheter
Hospital inpatients planned for dialysis catheter removal, based on standard clinical care and indications as identified by the primary nephrologist-in-charge.
|
A stand-alone disc-shaped device (approximately 5 cm in diameter and <1 cm thick) which can be placed over dressings.
Once switched on and put in place, continuous monitoring for bleeding takes place.
Detection occurs in 2 phases.
First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance.
Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin.
The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient.
The device can be used over transparent plastic dressings and does not require direct contact with blood.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of bleeding events detected by device
Time Frame: 0 to 6 hours after procedure
|
Number of bleeding episodes and detected by the device
|
0 to 6 hours after procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of False Alarms
Time Frame: 0 till 6 hours after procedure or till alarm triggered (whichever is earlier)
|
Number of times the device alarm was triggered with no bleeding is observed.
|
0 till 6 hours after procedure or till alarm triggered (whichever is earlier)
|
Number of Missed Bleeding Events
Time Frame: 0 to 6 hours after procedure
|
Number of episodes of bleeding but no device alarm was triggered.
|
0 to 6 hours after procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NHIC-I2D-1608124
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemorrhage
-
Region StockholmRecruitingRetinal Hemorrhage, Bilateral | Retinal Hemorrhage, Left Eye | Retinal Hemorrhage, Right EyeSweden
-
Al Hadi HospitalCompletedDiabetic Vitreous HemorrhageKuwait
-
Massachusetts Eye and Ear InfirmaryCompletedPost-operative HemorrhageUnited States
-
Panhandle Eye Group, LLPRecruitingDiabetic Vitreous HemorrhageMexico
-
Weill Medical College of Cornell UniversityThe Edward Grayson Fund for Retinal ResearchUnknownSubretinal Hemorrhage and Exudative MaculopathyUnited States
-
Tel-Aviv Sourasky Medical CenterIsrael Defense ForcesRecruiting
-
Ain Shams Maternity HospitalUnknownPost Operative HemorrhageEgypt
-
Asan Medical CenterUnknownPost Vitrectomy State | Recurrent Diabetic Vitreous HemorrhageKorea, Republic of
-
Assistance Publique - Hôpitaux de ParisTerminatedHemorrhage; Complicating DeliveryFrance
-
University of Sao PauloUnknownHemorrhage | RecurrentBrazil